bruceantin

02/01/2004 - "Moreover, an in vivo study using RPMI 8226 human-SCID xenografts demonstrated that bruceantin induced regression in early as well as advanced tumors, and these significant antitumor responses were facilitated in the absence of overt toxicity. "
01/01/2016 - "Bruceantin (BCT) is a natural product previously demonstrated to inhibit the growth of MM in RPMI 8226 cells-inoculated mouse xenograft models, and to cause regression in already established tumors. "
02/01/2004 - "Apoptosis was significantly elevated in tumors derived from animals treated with bruceantin. "
02/01/2004 - "Apoptosis was significantly elevated in tumors derived from animals treated with bruceantin (37%) as compared with the control tumors (14%). "
02/01/2004 - "Bruceantin treatment (2.5-5 mg/kg) resulted in a significant regression of tumors without overt toxicity. "

01/01/1983 - "The Eastern Cooperative Oncology Group (ECOG) conducted a Phase II trial of Bruceantin in malignant melanoma. "
01/01/1983 - "A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma."
01/01/1983 - "Bruceantin has only limited activity against malignant melanoma and is unlikely to contribute to systemic therapy of this disease, either as a single agent or in combinations of cytotoxic drugs."

08/01/1982 - "Phase II trial of bruceantin in metastatic breast carcinoma."
08/01/1982 - "A phase II evaluation of bruceantin was carried out in 15 patients with refractory metastatic breast cancer. "

02/01/2004 - "Responses of this type suggest bruceantin should be reinvestigated for clinical efficacy against hematological malignancies."
02/01/2004 - "These results suggest that bruceantin should be reinvestigated for clinical efficacy against multiple myeloma and other hematological malignancies."
11/01/1979 - "Bruceantin was administered to 33 patients with advanced solid tumors or hematologic neoplasms. "

02/01/2004 - "In sum, bruceantin interferes with the growth of leukemia, lymphoma, and myeloma cells in culture and xenograft models. "
02/01/2004 - "Recently, the activity of bruceantin has been studied with a number of leukemia, lymphoma, and myeloma cell lines. "
02/01/2004 - "Bruceantin has been shown to induce cell differentiation in a number of leukemia and lymphoma cell lines. "
01/01/2009 - "Here, we chose four structurally different chemical inhibitors of translation elongation: homoharringtonine, bruceantin, didemnin B and cycloheximide, and tested their ability to alter the chemoresistance of Emu-myc lymphomas harbouring lesions in Pten, Tsc2, Bcl-2, or eIF4E. "